生長抑制素類似物市場 - 全球產業規模、佔有率、趨勢、機會、預測：按類型、治療、最終用途、地區和競爭格局分類，2021-2031年

全球生長抑制素類似物市場預計將從 2025 年的 62.8 億美元成長到 2031 年的 94.9 億美元，複合年成長率為 7.12%。

這些合成藥物旨在模擬天然荷爾蒙生長抑制素的功能，主要作用是抑制生長激素、胰島素和多種胃腸道激素的分泌。此市場的成長主要受神經內分泌腫瘤（NETs）和肢端肥大症發生率上升的驅動。這些疾病需要長期治療以控制症狀並阻止腫瘤進展。美國癌症協會估計，到2024年，美國每年將新增約8,000例胃腸道神經內分泌腫瘤病例，凸顯了對持續治療方案的需求。

然而，市場擴張面臨一個重大障礙：學名藥的日益普及。主要品牌藥專利的到期使得低成本學名藥藥更容易進入市場，加劇了價格下行壓力，降低了原廠藥生產商的獲利能力。這一趨勢威脅著現有市場領導的盈利，因為它們正面臨著來自更具成本效益的替代品的激烈競爭。

市場促進因素

強大的臨床研發管線和加速的監管核准正在從根本上重塑全球生長抑制素類似物市場，一種強效的口服替代療法應運而生，成為標準注射劑型的有力替代方案。這種向非侵入性給藥方式的轉變有望減輕肢端肥大症和神經內分泌腫瘤患者長期注射的負擔，並提高長期治療依從性。例如，根據Crinetics Pharmaceuticals公司2024年3月公佈的3期PATHFNDR-2試驗結果，在研究性口服帕佐汀組中，56%的患者胰島素樣生長因子1 (IGF-1) 水平恢復正常，而安慰劑組僅為5%。這種口服製劑的高效性預示著疾病管理模式轉移，並有望透過改善患者偏好和臨床療效，推動未來市場擴張。

同時，生長抑制素類似物在核醫和治療診斷學（治療性診斷）領域的應用，正拓展這些藥物的治療效用，使其不再侷限於症狀控制，而是能夠根除標靶腫瘤。胜肽受體放射性核種療法（PRRT）是一種利用放射性標記的類似物將細胞毒性輻射特異性遞送至生長抑制素受體陽性細胞的技術，目前正經歷著快速的商業性化應用。根據諾華公司於2024年10月發布的2024年第三季財報，其放射性配體療法Lutasera的季度銷售額達到1.9億美元，年增19%，反映出市場對標靶核醫學介入的強勁需求。儘管創新正在加速發展，但成熟的治療方法仍然是重要的收入來源。諾華指出，Sandostatin得定集團2023年的淨銷售額約為12.8億美元，凸顯了市場對基礎生長抑制素類似物療法的持續依賴。

市場挑戰

學名藥的日益普及對全球生長抑制素類似物市場的商業性擴張構成重大障礙。主要品牌藥專利保護期的結束使得低成本替代品得以進入市場，從根本上擾亂了現有製藥企業的收入結構。隨著這些學名藥滲透市場，價格下行壓力將急劇上升，迫使原廠藥企業削減成本以保持競爭力，否則將面臨市場佔有率大幅下降的風險。這種從高價值品牌藥轉向以銷售主導的學名藥的轉變，嚴重限制了企業維持該治療領域研發持續投入所需的利潤空間。

這種價值侵蝕的趨勢得到了反映生長抑制素類似物當前處境的產業數據的佐證。根據美國可及藥品協會（Association for Accessible Medicines）2024年的報告，學名藥和生物相似藥占美國所有處方箋的90%，但僅佔藥品總支出的約13%。處方量與經濟回報之間如此巨大的差距清晰地揭示了這項挑戰的機制。患者獲得Octreotide和Lanreotide等治療方法的機會可能會增加，但收入潛力與實際使用率的脫鉤將抑制整體市場價值。

市場趨勢

先進的、以患者為中心的自行注射裝置的普及正在重塑市場格局，其優勢在於優先考慮便利性和治療依從性。與需要醫療專業人員注射的傳統肌肉注射製劑不同，現代皮下緩釋製劑整合了預填充式注射器，使患者能夠獨立管理治療。這種朝向使用者友善給藥系統的轉變，為成熟品牌帶來了顯著的競爭優勢，使其即使在充滿挑戰的市場環境中也能保持成長動能。根據益普生於2025年2月發布的《2024年全年業績報告》，皮下緩釋製劑生長激素（somatrin）的銷售額同比成長5.6%，表明市場持續青睞整合於裝置中的製劑，以最大限度地減少慢性病管理中的後勤負擔。

同時，新一代多受體標靶類似物的研發正在拓展對標準療法抗藥性患者的治療選擇。第一代類似物主要與受體亞型2結合，而新一代藥物如Pasireotide則對包括受體亞型1、3和5在內的多種受體具有高親和性，在複雜病例中控制激素分泌過多方面療效較佳。這種臨床差異化顯著促進了內分泌學領域內此類藥物的商業性應用。根據RecoDati於2025年2月發布的“2024會計年度初步業績報告”，內分泌部門淨銷售額達到3.217億歐元，年增32.8%。這主要得益於多受體類似物Signifall的兩位數成長，顯示市場對更廣泛的治療選擇有著強勁的需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：生長抑制素類似物的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（Octreotide、Lanreotide、Pasireotide）
  • 治療類別（肢端肥大症、庫欣氏症候群、神經內分泌腫瘤、類癌症候群、其他）
  • 依用途（醫院/診所、門診手術中心、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美生長抑制素類似物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲生長抑制素類似物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區生長抑制素類似物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲生長抑制素類似物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲生長抑制素類似物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球生長抑制素類似物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Bayer AG
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Midatech Pharma plc
• Crinetics Pharmaceuticals Inc.
• Peptron Inc.
• Teva Pharmaceutical Industries Ltd.
• Camurus AB
• Mylan NV

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Somatostatin Analogs Market is projected to expand from USD 6.28 Billion in 2025 to USD 9.49 Billion by 2031, registering a CAGR of 7.12%. These synthetic pharmacological agents are engineered to mimic the function of the natural hormone somatostatin, serving primarily to inhibit the secretion of growth hormone, insulin, and various gastrointestinal hormones. The market is largely propelled by the rising prevalence of neuroendocrine tumors (NETs) and acromegaly, conditions that require long-term management therapies to control symptoms and halt tumor progression. Highlighting the demand for sustained therapeutic options, the American Cancer Society estimated that approximately 8,000 neuroendocrine tumors originating in the gastrointestinal tract would be diagnosed annually in the United States in 2024.

However, market expansion faces a significant obstacle regarding the increasing availability of generic formulations. The expiration of patents for key branded drugs has facilitated the entry of lower-cost generic alternatives, which exerts downward pricing pressure and reduces the revenue potential for original manufacturers. This trend challenges the profitability of established market leaders as they face intensified competition from cost-effective substitutes.

Market Driver

A robust clinical pipeline and accelerated regulatory approvals are fundamentally reshaping the Global Somatostatin Analogs Market by introducing potent oral alternatives to standard injectables. This shift towards non-invasive delivery methods addresses the burden of chronic injections for patients with acromegaly and neuroendocrine tumors, promising to enhance long-term treatment adherence. For instance, according to Crinetics Pharmaceuticals' March 2024 'Phase 3 PATHFNDR-2 Study Results', 56% of participants receiving the investigational oral drug paltusotine achieved normalized insulin-like growth factor 1 (IGF-1) levels, compared to just 5% of those on placebo. This high efficacy rate for an oral agent signals a potential paradigm shift in disease management, likely driving future market expansion through improved patient preference and clinical outcomes.

Simultaneously, the integration of somatostatin analogs into nuclear medicine and theranostics is expanding the therapeutic utility of these agents beyond symptom control to targeted tumor eradication. Peptide receptor radionuclide therapy (PRRT) utilizes radiolabeled analogs to deliver cytotoxic radiation specifically to somatostatin receptor-positive cells, a modality experiencing rapid commercial uptake. According to Novartis' 'Q3 2024 Financial Results' released in October 2024, sales of the radioligand therapy Lutathera rose by 19% year-on-year to reach $190 million for the quarter, reflecting strong demand for targeted nuclear interventions. While innovation accelerates, established therapies remain vital revenue generators; Novartis noted that in 2023, the Sandostatin Group achieved total net sales of approximately $1.28 billion, underscoring the enduring market reliance on foundational somatostatin analog treatments.

Market Challenge

The increasing availability of generic formulations acts as a significant barrier to the commercial expansion of the global somatostatin analogs market. The loss of patent exclusivity for major branded drugs has enabled the entry of low-cost alternatives, which fundamentally disrupts the revenue structure of established pharmaceutical manufacturers. As these generic versions permeate the market, they create intense downward pricing pressure, forcing originators to lower costs to remain competitive or risk ceding substantial market share. This shift from high-value branded therapies to volume-driven generics severely limits the profit margins required to sustain continued investment in research and development for this therapeutic class.

This trend of value erosion is substantiated by broader industry data that reflects the environment somatostatin analogs now navigate. According to the Association for Accessible Medicines, in its 2024 report, generic and biosimilar medicines accounted for 90% of all prescriptions filled in the United States but represented only approximately 13% of total drug spending. This stark disparity between prescription volume and financial return illustrates the mechanics of the challenge; while patient access to therapies like octreotide and lanreotide may increase, the overall market value is constrained as revenue potential decouples from utilization rates.

Market Trends

The proliferation of advanced patient-centric self-injection devices is reshaping the market by prioritizing convenience and treatment adherence. Unlike traditional intramuscular formulations that often require administration by healthcare professionals, modern subcutaneous depots integrated with pre-filled syringes empower patients to manage their therapy independently. This shift towards user-friendly delivery systems has created a significant competitive advantage, allowing established brands to sustain momentum even amidst challenging market conditions. According to Ipsen's 'Full Year 2024 Results' published in February 2025, sales of the subcutaneous depot Somatuline grew by 5.6% year-on-year, illustrating the enduring market preference for device-integrated formulations that minimize the logistical burden of chronic disease management.

Concurrently, the development of next-generation multi-receptor targeted analogs is expanding therapeutic possibilities for patients refractory to standard treatments. While first-generation analogs primarily bind to receptor subtype 2, next-generation agents like pasireotide exhibit high affinity for multiple receptor subtypes, including 1, 3, and 5, offering superior efficacy in controlling hormone hypersecretion in complex cases. This clinical differentiation is driving substantial commercial uptake in the specialized endocrinology sector. According to Recordati's 'Preliminary Results for Full Year 2024' released in February 2025, the Endocrinology franchise achieved net revenue of €321.7 million, a 32.8% increase fueled by the double-digit growth of the multi-receptor analog Signifor, signaling strong demand for broader-spectrum therapeutic options.

Key Market Players

• Bayer AG
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Midatech Pharma plc
• Crinetics Pharmaceuticals Inc.
• Peptron Inc.
• Teva Pharmaceutical Industries Ltd.
• Camurus AB
• Mylan N.V

Report Scope

In this report, the Global Somatostatin Analogs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Somatostatin Analogs Market, By Type

• Octreotide
• Lanreotide
• Pasireotide

Somatostatin Analogs Market, By Treatment

• Acromegaly
• Cushing's Syndrome
• Neuroendocrine Tumors
• Carcinoid Syndrome
• Others

Somatostatin Analogs Market, By End Use

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Somatostatin Analogs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Somatostatin Analogs Market.

Available Customizations:

Global Somatostatin Analogs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Somatostatin Analogs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Octreotide, Lanreotide, Pasireotide)
  • 5.2.2. By Treatment (Acromegaly, Cushing's Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Others)
  • 5.2.3. By End Use (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Somatostatin Analogs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Somatostatin Analogs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada Somatostatin Analogs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico Somatostatin Analogs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End Use

7. Europe Somatostatin Analogs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Somatostatin Analogs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End Use
  • 7.3.2. France Somatostatin Analogs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Somatostatin Analogs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Somatostatin Analogs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Somatostatin Analogs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By End Use

8. Asia Pacific Somatostatin Analogs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Somatostatin Analogs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Somatostatin Analogs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan Somatostatin Analogs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea Somatostatin Analogs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Somatostatin Analogs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By End Use

9. Middle East & Africa Somatostatin Analogs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Somatostatin Analogs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End Use
  • 9.3.2. UAE Somatostatin Analogs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End Use
  • 9.3.3. South Africa Somatostatin Analogs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End Use

10. South America Somatostatin Analogs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Somatostatin Analogs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By End Use
  • 10.3.2. Colombia Somatostatin Analogs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By End Use
  • 10.3.3. Argentina Somatostatin Analogs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Somatostatin Analogs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Pfizer Inc.
• 15.4. Sun Pharmaceutical Industries Ltd.
• 15.5. Midatech Pharma plc
• 15.6. Crinetics Pharmaceuticals Inc.
• 15.7. Peptron Inc.
• 15.8. Teva Pharmaceutical Industries Ltd.
• 15.9. Camurus AB
• 15.10. Mylan N.V

16. Strategic Recommendations

17. About Us & Disclaimer